Company Overview

Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing drug delivery technologies and specialty biopharmaceutical products. The company operates primarily in the biotechnology and pharmaceutical sectors, with a business model centered on licensing its proprietary ENHANZE® drug delivery platform to large pharmaceutical partners. ENHANZE® is based on recombinant human hyaluronidase technology designed to enable subcutaneous administration of injectable biologics that are traditionally delivered intravenously. Halozyme also markets internally developed products and receives revenue through royalties, milestone payments, product sales, and licensing agreements.

The company’s primary revenue drivers are royalties and collaboration revenues generated from partnered products utilizing ENHANZE®, including therapies commercialized by major pharmaceutical companies such as Roche, Johnson & Johnson, Bristol Myers Squibb, Pfizer, and argenx. Halozyme’s customer base primarily includes global pharmaceutical manufacturers, healthcare providers, and specialty therapeutic markets in oncology, immunology, hematology, and rare diseases. Founded in 1998 and headquartered in San Diego, California, the company evolved from a specialty enzyme therapeutics developer into a platform-focused biotechnology licensing company with a broad portfolio of strategic pharmaceutical partnerships.

Business Operations

Halozyme organizes its operations primarily around its proprietary ENHANZE® platform and commercial products. The company generates revenue through licensing agreements, collaborative development arrangements, royalties on commercialized partner products, milestone payments, and product sales. Its technology enables pharmaceutical companies to convert intravenous biologic therapies into more convenient subcutaneous formulations, potentially reducing administration time and improving patient access. Commercialized products using ENHANZE® technology have been approved in multiple markets across oncology, immunology, and autoimmune disease indications.

The company maintains partnerships with numerous global pharmaceutical companies, including Roche, Janssen (Johnson & Johnson), Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, and argenx. Halozyme controls a substantial intellectual property portfolio related to recombinant human hyaluronidase technology and drug delivery methods. Operations are primarily U.S.-based, though revenue exposure is global due to the international commercialization activities of its partners. The company historically commercialized products such as Hylenex® recombinant and has emphasized high-margin royalty and licensing operations as a central component of its business model.

Strategic Position & Investments

Halozyme’s strategic direction has focused on expanding adoption of the ENHANZE® platform through additional licensing agreements, lifecycle management opportunities for biologic drugs, and broader penetration into large therapeutic categories. The company has increasingly positioned itself as a platform and royalty-driven biotechnology company rather than a traditional fully integrated drug developer. This strategy has enabled Halozyme to scale revenue through long-term royalty streams tied to partner commercialization efforts without assuming full global commercialization costs.

The company has entered multiple long-duration licensing and co-development agreements with leading pharmaceutical manufacturers and has continued investing in intellectual property expansion and formulation technologies. Halozyme has also explored applications of ENHANZE® across emerging biologic modalities and large-volume subcutaneous drug administration. Public filings and investor materials indicate continued focus on oncology, immunology, and specialty therapeutics as key growth areas. The company’s strategic positioning is strengthened by regulatory approvals for numerous partnered products across the United States, Europe, and Asia-Pacific markets.

Geographic Footprint

Halozyme is headquartered in San Diego, California, and operates primarily from the United States, though its commercial reach is global through pharmaceutical licensing partners. Products utilizing the company’s ENHANZE® technology are marketed across North America, Europe, Asia-Pacific, and other international healthcare markets. The company’s international exposure is driven largely by its partners’ regulatory approvals and commercial distribution networks.

The company maintains strategic influence in major pharmaceutical markets including the United States, European Union, Japan, and other developed healthcare systems where biologic therapies represent significant market demand. Halozyme’s partnered products have received approvals from regulators including the U.S. Food and Drug Administration and the European Medicines Agency. International royalty streams and milestone payments represent an important component of the company’s financial profile and operational reach.

Leadership & Governance

Halozyme’s leadership team emphasizes platform expansion, capital-efficient growth, and long-term strategic pharmaceutical partnerships. The company’s governance structure reflects its transition into a technology licensing and royalty-focused biotechnology business. Public communications and investor presentations consistently emphasize disciplined capital allocation, intellectual property protection, and diversification of partnered commercial assets.

Key executives include:

• Helen Torley, M.B. Ch.B., M.R.C.P. – President and Chief Executive Officer
• Nicole Labrosse – Senior Vice President, Chief Financial Officer
• Michael Labarre – Chief Technical Operations Officer
• Daryl Yoshizumi – Senior Vice President, General Counsel and Corporate Secretary
• Dr. H. Michael Shepard – Senior Vice President, Chief Scientific Officer

The company’s board and executive leadership have highlighted long-term royalty generation, expansion of commercial partnerships, and continued advancement of subcutaneous biologic delivery technologies as central strategic priorities.